Serum amyloid a, a potential biomarker both in serum and tissue, correlates with ovarian cancer progression

Abstract

Objective: Ovarian cancer is the most fatal gynecologic malignancy worldwide due to delayed diagnosis as well as recurrence and drug resistance. Thus, a new type of ovarian cancer treatment prediction biomarker is urgently needed to supplement existing tools. Methods: One hundred patients operated on due to ovarian tumor were enrolled in this study. Meanwhile, one hundred ovarian benign patients and thirty healthy women were selected as control groups. Levels of SAA, CA125 and HE4 were assessed using standard laboratory protocols. 5 ovarian cancer tissues and paracancerous tissues were collected and than stored at -80℃ until the qRT-PCR assay was conducted.Results: The ROC curve of SAA concentration in ovarian cancer was plotted to obtain the area under the curve AUC = 0.889, the cut-off value 17.05 mg/L, the sensitivity 78.4% and specificity 86.5%. The results by logistic regression analysis revealed that there was significant correlation between the level of serum SAA and clinical stage and lymph node and distant metastasis. Compared with pre-treatment, the level of serum SAA decreased significantly after treatment. qRT-PCR assay revealed that the mRNA of SAA-1 and SAA-4 was much higher in cancer tissues than in adjacent tissues, and MMPs was up-regulation including MMP-1, MMP-9 and MMP- 12 in OVCAR-3 cell stimulated by SAA and transwell assay revealed that SAA could promote OVCAR-3 cell migration. Moreover, SAA can regulate EMT markers and promote Akt pathway activation.Conclusion: In summary, our results demonstrated that SAA may be a potential diagnosis and treatment prediction biomarker. SAA promote OVCAR-3 cell migration by regulating MMPs and EMT which may correlate with Akt pathway activation.

Retracted: Arecoline induces epithelial‐mesenchymal transformation and promotes metastasis of oral cancer by SAA1 expression

“…34 Another study showed that SAAs, including SAA1 and SAA4, promoted OVCAR-3 cell migration by regulating matrix metalloproteinases (MMPs) and EMT, which may correlate with Akt pathway activation. 35 In addition, Chang et al reported that the levels of SAA1 were increased in OSCC patients with relapse. 36 In the current study, we identified, using RNA-seq screening, that SAA1 is the most significantly upregulated gene in arecoline-treated OSCC cells.…”